Creabilis Raises $20M To Develop Dermatology Drugs
Creabilis said it acquired a second round of funding from first-time investor Abbott as well as existing investors Neomed Management AS and Sofinnova Partners. The biotech company, which has offices in Luxembourg, Italy and the U.K., also raised money from Italian investors it did not name.
Creabilis will use the money in part to continue development...
To view the full article, register now.